Private company

MERCK SHARP & DOHME LLC

American pharmaceutical preparations company, incorporated in New Jersey. Summary from the record

Last updated Oct 21, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersNJ¹

See how the biggest companies compare on our leaderboards

Corporate structure

MERCK SHARP & DOHME LLC is part of a group headed by Merck & Co.. 349 entities, 69 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Merck & Co. Rahway, New Jersey, United States
- MERCK SHARP & DOHME LLC NJ
  - Harpoon Therapeutics, Inc. Stake · South San Francisco, California, United States
- MSD Sharp & Dohme GmbH München, Germany
- Merck (Japan) Subsidiary · Tokyo, Japan
- Merck Sharp & Dohme Latvija, SIA Subsidiary · Riga, Latvia
- Merck Sharp & Dohme, UAB Subsidiary · Vilnius, Lithuania
- MSD (Netherlands) Subsidiary · Amsterdam, Netherlands
- MSD Norway AS Subsidiary · Drammen, Norway
- Sirna Therapeutics Subsidiary · San Francisco
- 7728026 Canada Inc. Subsidiary · Canada
- Abceutics, Inc. Subsidiary · Delaware, United States
- Abmaxis Inc. Subsidiary · Delaware, United States
- Acceleron Pharma Inc. Subsidiary · Delaware, United States
- Afferent Pharmaceuticals, Inc. Subsidiary · Delaware, United States
- Agrident GmbH Subsidiary · Germany
- Allflex (China) Intelligent Technology Co. Ltd. Subsidiary · China
- Allflex Argentina S.A. Subsidiary · Argentina
- Allflex Australia Pty. Ltd. Subsidiary · Australia
- Allflex Dan-Mark ApS Subsidiary · Denmark
- Allflex Europe S.A.S. Subsidiary · France
- Allflex Group Germany GmbH Subsidiary · Germany
- ALLFLEX INDIA PRIVATE LIMITED Subsidiary · Gurugram, India
- Allflex Maroc S.A.R.L. Subsidiary · Morocco
- Allflex New Zealand Subsidiary · New Zealand
- Allflex Polska Spolka z ograniczona odpowiedzialnoscia Subsidiary · Poland
- Allflex Romania S.R.L. Subsidiary · Romania
- and 317 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Leadership

Who has led MERCK SHARP & DOHME LLC, and when. Pick a name to see everywhere that person has worked.

President

2010201520202025

PresidentWillie A. Deese Feb 6, 2006 to Mar 3, 2008²
PresidentBradley T. Sheares Feb 14, 2006 to Mar 7, 2006³
PresidentDavid W. Anstice Feb 17, 2006 to Mar 7, 2006⁴
PresidentOlsen Per Wold Feb 17, 2006 to Mar 7, 2006⁵
PresidentMargaret G. McGlynn Mar 7, 2006 to Apr 27, 2009⁶
PresidentPeter Loescher May 4, 2006 to Mar 6, 2007⁷
PresidentAdam H. Schechter Oct 5, 2006 to Nov 4, 2009⁸

Board members and other officers (33)

V-P & Chief Com. OfficerAdele D. Ambrose Jan 7, 2008 to Nov 4, 2009⁹
Exec.VP & President, MMDWillie A. Deese Mar 4, 2008 to Nov 4, 2009¹⁰
Exec.V-P, Strategy InitiativesDavid W. Anstice Mar 1, 2007 to Apr 10, 2008¹¹
Exec.V-P & Pres., Global HHKenneth Frazier Aug 3, 2007 to Nov 4, 2009¹²
Exec. V.P. & C.F.O.Peter N. Kellogg Aug 17, 2007 to Nov 4, 2009¹³
Sr.VP Global P&S & CIOJ. Chris Scalet Jan 10, 2006 to Nov 4, 2009¹⁴
V.P. & TreasurerCaroline Dorsa Feb 8, 2006 to Jan 17, 2007¹⁵
V.P., ControllerRichard C. Henriques Jr. Feb 8, 2006 to Mar 7, 2006¹⁶
Exec.V.P.& C.F.O./Pres.HHAJudy C. Lewent Feb 10, 2006 to Aug 9, 2007¹⁷
V-P,Sec. & Asst.Gen.CounselCelia A. Colbert Feb 15, 2006 to Nov 4, 2009¹⁸
Vice President, Public AffairsJoan E. Wainwright Mar 7, 2006 to Mar 7, 2006¹⁹
Pres., Merck Research Labs.Peter S. Kim Mar 7, 2006 to Nov 4, 2009²⁰
Vice President, Public AffairsSteven B. Kelmar Aug 31, 2006 to Sep 5, 2007²¹
Sr. V-P, Human ResourcesWeir Mirian M. Graddick Sep 6, 2006 to Nov 4, 2009²²
V-P, ControllerJohn Canan Sep 11, 2006 to Nov 4, 2009²³
Chief Marketing OfficerWendy L. Yarno Oct 6, 2006 to Mar 4, 2008²⁴
Board memberCarlos E. Represas Feb 25, 2009 to Jan 20, 2011²⁵
Board memberThomas R. Cech May 29, 2009 to Nov 4, 2009²⁶
Board memberLeslie A. Brun Jul 22, 2008 to Nov 4, 2009²⁷
Board memberSteven F. Goldstone Sep 25, 2007 to Nov 4, 2009²⁸
Board memberTom Glocer Nov 28, 2007 to Nov 4, 2009²⁹
Board memberHarry R. Jacobson Dec 20, 2007 to Nov 4, 2009³⁰
Board memberAnne M. Tatlock Jan 4, 2006 to Nov 4, 2009³¹
Board memberLawrence A. Bossidy Jan 4, 2006 to Apr 3, 2007³²
Board memberPeter C. Wendell Jan 4, 2006 to Nov 4, 2009³³
Board memberRochelle B. Lazarus Jan 4, 2006 to Nov 4, 2009³⁴
Board memberSamuel O. Thier Md. Jan 4, 2006 to Nov 4, 2009³⁵
Board memberWendell Weeks Jan 4, 2006 to Nov 4, 2009³⁶
Board memberWillam N. Kelley Jan 4, 2006 to Nov 4, 2009³⁷
Board memberWilliam B. Harrison Jr. Jan 4, 2006 to Nov 4, 2009³⁸
Board memberThomas E. Shenk May 2, 2006 to Nov 4, 2009³⁹
General counselBruce N. Kuhlik Aug 2, 2007 to Nov 4, 2009⁴⁰
General counselKenneth Frazier Feb 17, 2006 to Mar 6, 2007⁴¹

Filings

28 filings to the SEC since October 2021: 28 other. The latest 20:

The 28 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

MERCK SHARP & DOHME LLC has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

Harpoon Therapeutics, Inc.SC 13D/A Jan 18, 2024 to Mar 11, 2024⁴²

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$28.1B 2012–2026

Federal contracts $28.1B

Figures by year

Year	Federal contracts	Total
2026	$2.0B	$2.0B
2025	$2.5B	$2.5B
2024	$2.9B	$2.9B
2023	$2.3B	$2.3B
2022	$2.1B	$2.1B
2021	$4.0B	$4.0B
2020	$1.6B	$1.6B
2019	$1.8B	$1.8B
2018	$1.4B	$1.4B
2017	$1.6B	$1.6B
2016	$1.7B	$1.7B
2015	$1.4B	$1.4B
2014	$1.5B	$1.5B
2013	$1.2B	$1.2B
2012	$448.9K	$448.9K

Federal awards

Obligated amounts from USAspending.gov⁴³, by calendar year, 2012–2026, for its registration. Obligations are what agencies committed, not always what was paid out. Contracts pay for goods and services; grants, loans and direct payments are assistance. Loans are charted at the face value of the loans listed here. An award’s amount below is its lifetime total, and some began before the years charted.

Largest contracts

Jun 7, 2021$2.2B from Department of the Army: Covid-19 oral antiviral mk-4482 (molnupiravir)⁴⁴ To MERCK SHARP & DOHME LLC Award W911QY21C0031
Apr 1, 2014$1.5B from Centers for Disease Control and Prevention: Vsccine for children (vfc) 2014⁴⁵ To MERCK SHARP & DOHME LLC Award HHSD200201458150C
Apr 1, 2017$1.5B from Centers for Disease Control and Prevention: Igf::ot::igf 2017 vaccines for children⁴⁶ To MERCK SHARP & DOHME LLC Award HHSD200201793273C
Apr 1, 2013$1.4B from Centers for Disease Control and Prevention: Vaccine for children 2013⁴⁷ To MERCK SHARP & DOHME LLC Award HHSD200201354509C
Sep 28, 2017$236.3M from Office of Assistant Secretary for Preparedness and Response: Igf::ot::igf⁴⁸ To MERCK SHARP & DOHME LLC Award HHSO100201700012C

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMERCK SHARP & DOHME LLC filings on SEC EDGAR
2
SEC EDGARWillie A. Deese, President
3
SEC EDGARBradley T. Sheares, President
4
SEC EDGARDavid W. Anstice, President
5
SEC EDGAROlsen Per Wold, President
6
SEC EDGARMargaret G. McGlynn, President
7
SEC EDGARPeter Loescher, President
8
SEC EDGARAdam H. Schechter, President
9
SEC EDGARAdele D. Ambrose, V-P & Chief Com. Officer
10
SEC EDGARWillie A. Deese, Exec.VP & President, MMD
11
SEC EDGARDavid W. Anstice, Exec.V-P, Strategy Initiatives
12
SEC EDGARKenneth Frazier, Exec.V-P & Pres., Global HH
13
SEC EDGARPeter N. Kellogg, Exec. V.P. & C.F.O.
14
SEC EDGARJ. Chris Scalet, Sr.VP Global P&S & CIO
15
SEC EDGARCaroline Dorsa, V.P. & Treasurer
16
SEC EDGARRichard C. Henriques Jr., V.P., Controller
17
SEC EDGARJudy C. Lewent, Exec.V.P.& C.F.O./Pres.HHA
18
SEC EDGARCelia A. Colbert, V-P,Sec. & Asst.Gen.Counsel
19
SEC EDGARJoan E. Wainwright, Vice President, Public Affairs
20
SEC EDGARPeter S. Kim, Pres., Merck Research Labs.
21
SEC EDGARSteven B. Kelmar, Vice President, Public Affairs
22
SEC EDGARWeir Mirian M. Graddick, Sr. V-P, Human Resources
23
SEC EDGARJohn Canan, V-P, Controller
24
SEC EDGARWendy L. Yarno, Chief Marketing Officer
25
SEC EDGARCarlos E. Represas, Board member
26
SEC EDGARThomas R. Cech, Board member
27
SEC EDGARLeslie A. Brun, Board member
28
SEC EDGARSteven F. Goldstone, Board member
29
SEC EDGARTom Glocer, Board member
30
SEC EDGARHarry R. Jacobson, Board member
31
SEC EDGARAnne M. Tatlock, Board member
32
SEC EDGARLawrence A. Bossidy, Board member
33
SEC EDGARPeter C. Wendell, Board member
34
SEC EDGARRochelle B. Lazarus, Board member
35
SEC EDGARSamuel O. Thier Md., Board member
36
SEC EDGARWendell Weeks, Board member
37
SEC EDGARWillam N. Kelley, Board member
38
SEC EDGARWilliam B. Harrison Jr., Board member
39
SEC EDGARThomas E. Shenk, Board member
40
SEC EDGARBruce N. Kuhlik, General counsel
41
SEC EDGARKenneth Frazier, General counsel
42
SEC EDGARMERCK SHARP & DOHME LLC SC 13D/A on Harpoon Therapeutics, Inc.
43
USAspending.govUSAspending.gov recipient profile: MERCK SHARP & DOHME LLC
44
USAspending.govW911QY21C0031: Department of the Army
45
USAspending.govHHSD200201458150C: Centers for Disease Control and Prevention
46
USAspending.govHHSD200201793273C: Centers for Disease Control and Prevention
47
USAspending.govHHSD200201354509C: Centers for Disease Control and Prevention
48
USAspending.govHHSO100201700012C: Office of Assistant Secretary for Preparedness and Response